GPCR (Structure Therapeutics) Payments of Debt: $0.00 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GPCR Structure Therapeutics Inc GPCR
32 GF Score
Price $50.80
View Full Analysis

What is Structure Therapeutics Payments of Debt?

Structure Therapeutics GPCR +0.70% 32 Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates GPCR with a GF Score™ of 32/100.

Structure Therapeutics's Payments of Debt for the three months ended in Mar. 2026 was $0.00 Mil.

Structure Therapeutics's Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.

Structure Therapeutics Payments of Debt Related Terms

Structure Therapeutics Payments of Debt Historical Data

* Premium members only.

The historical data trend for Structure Therapeutics's Payments of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Structure Therapeutics Payments of Debt Chart

Structure Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Payments of Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Structure Therapeutics Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Payments of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
GPCR
32GF Score
Structure Therapeutics Inc GPCR
Payments of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Structure Therapeutics Payments of Debt Calculation

Payments of Debt represents all the cash outflow from debt, including both long-term debt and short-term debt.

Payments of Debt for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Payments of Debt →
What does a Payments of Debt of $0.00 Mil mean?
Structure Therapeutics (GPCR) has a Payments of Debt of $0.00 Mil as of Mar. 2026. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Structure Therapeutics and its competitors.
Is Structure Therapeutics' Payments of Debt too high?
Structure Therapeutics' current Payments of Debt is $0.00 Mil. Overall, Structure Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Structure Therapeutics' Payments of Debt compare to PBLS and IDYA?
Structure Therapeutics' Payments of Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Payments of Debt for a Biotechnology company?
A good Payments of Debt depends on the Biotechnology industry context. However, Payments of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Payments of Debt mean?
A high Payments of Debt can signal that a stock is expensive relative to its fundamentals. Payments of Debt is all the cash outflow from debt, including both long-term debt and short-term debt. View historical data on Structure Therapeutics and its competitors. Structure Therapeutics's current Payments of Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Structure Therapeutics stock overvalued right now?
Structure Therapeutics (GPCR) has a current Payments of Debt of $0.00 Mil. The current Payments of Debt is $0.00 Mil. Structure Therapeutics' overall GF Score™ is 32/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Payments of Debt calculated?
Payments of Debt is calculated from a company's financial statements. For Structure Therapeutics (GPCR), the current Payments of Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Structure Therapeutics Business Description

Address 601 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
32GF Score

Get the complete analysis for GPCR

Payments of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$50.80
Price